skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pitavastatin: evidence for its place in treatment of hypercholesterolemia

Review

(1662) Views  (773) Full article downloads

Authors: Peter Alagona, Jr

Published Date October 2010 Volume 2010:5 Pages 91 - 105
DOI: http://dx.doi.org/10.2147/CE.S8008

Peter Alagona, Jr
Penn State Heart and Vascular Institute, Penn State College of Medicine, Hershey, Pennsylvania, USA

Abstract: Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are the most potent pharmacologic agents for lowering total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). They have become an accepted standard of care in the treatment of patients with known atherosclerotic cardiovascular disease (secondary prevention) and also those at increased risk of cardiovascular events. There are currently six statin drugs commercially available in the US. Although they are chemically similar and have the same primary mechanisms of action in lowering TC and LDL-C, there are differences in their efficacy or potency, metabolism, drug–drug interactions, and individual tolerability. Considering the numbers of patients who need LDL-C-lowering therapy and questions of individual tolerance and therapeutic response, having a variety of agents to choose from is beneficial for patient care. This paper presents background information on statin treatment and reviews data regarding a new agent, pitavastatin, which has recently been approved for clinical use.

Keywords: HMG CoA reductase inhibitors, statins, pitavastatin, class effect, low-density lipoprotein




 

Other articles by Dr Peter Alagona



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals
Health literacy and health seeking behavior among older men in a middle-income nation
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Erratum
Biosimilars: an overview
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University